Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations

BMJ Open

Volumn 3, Issue 12, 2013, Pages

  O'Reilly, Philip J ^a   Jackson, Patricia L ^a   Wells, J Michael ^a   Dransfield, Mark T ^a   Scanlon, Paul D ^b   Blalock, J Edwin ^a  

^a and Clinical Center   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; COLLAGEN; GELATINASE B; MYELOPEROXIDASE; PLACEBO; PROLINE GLYCINE PROLINE; TRIPEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; EX VIVO STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORBIDITY; MULTICENTER STUDY; SINGLE BLIND PROCEDURE; SPUTUM ANALYSIS; SPUTUM LEVEL; TREATMENT DURATION;

EID: 84892607699     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-004140     Document Type: Article

References (23)

1. Weathington NM, van Houwelingen AH, Noerager BD, et al. A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat Med 2006;12:317-23. (Pubitemid 43355080)
2. Gaggar A, Jackson PL, Noerager BD, et al. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol 2008;180:5662-9.
3. O'Reilly PJ, Hardison MT, Jackson PL, et al. Neutrophils contain prolyl endopeptidase and generate the chemotactic peptide, PGP, from collagen. J Neuroimmunol 2009;217:51-4.
4. Snelgrove RJ, Jackson PL, Hardison MT, et al. A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation. Science 2010;330:90-4.
5. O'Reilly P, Jackson PL, Noerager B, et al. N-alpha-PGP and PGP, potential biomarkers and therapeutic targets for COPD. Respir Res 2009;10:38.
6. Hardison MT, Galin FS, Calderon CE, et al. The presence of a matrix-derived neutrophil chemoattractant in bronchiolitis obliterans syndrome after lung transplantation. J Immunol 2009;182:4423-31.
7. Croxton TL, Weinmann GG, Senior RM, et al. Clinical research in chronic obstructive pulmonary disease: needs and opportunities. Am J Respir Crit Care Med 2003;167:1142-9. (Pubitemid 36469297)
8. Vestbo J, Rennard S. Chronic obstructive pulmonary disease biomarker(s) for disease activity needed-urgently. Am J Respir Crit Care Med 2010;182:863-4.
9. Clement A, Tamalet A, Leroux E, et al. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 2006;61:895-902. (Pubitemid 44570311)
10. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012;380:660-7.
11. Martinez FJ, Curtis JL, Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008;3:331-50.
12. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689-98.
13. Verleden SE, Vandooren J, Vos R, et al. Azithromycin decreases MMP-9 expression in the airways of lung transplant recipients. Transpl Immunol 2011;25:159-62.
14. Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008;177:148-55.
15. Braber S, Koelink PJ, Henricks PA, et al. Cigarette smoke-induced lung emphysema in mice is associated with prolyl endopeptidase, an enzyme involved in collagen breakdown. Am J Physiol Lung Cell Mol Physiol 2011;300:L255-65.
16. van Houwelingen AH, Weathington NM, Verweij V, et al. Induction of lung emphysema is prevented by L-arginine-threonine-arginine. FASEB J 2008;22:3403-8.
17. Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-13. (Pubitemid 30329036)
18. Woodruff PG. Novel outcomes and end points: biomarkers in chronic obstructive pulmonary disease clinical trials. Proc Am Thorac Soc 2011;8:350-5.
19. Papi A, Luppi F, Franco F, et al. Pathophysiology of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006;3:245-51. (Pubitemid 43668189)
20. Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005;128:1995-2004. (Pubitemid 41507533)
21. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38.
22. Woodruff PG, Albert R, Chatila W, et al. Analysis of blood biomarkers in the NIH-sponsored azithromycin in COPD Study. Am J Respir Crit Care Med 2012;185:A1007.
23. Wells JM, Jackson PL, O'Reilly PJ, et al. Selective inhibition of leukotriene A4 hydrolase aminopeptidase activity occurs in COPD and reflects clinical outcomes. Am J Respir Crit Care Med 2012;185: A1422.